NervGen Pharma Corp. (TSXV:NGEN)
Canada · Delayed Price · Currency is CAD | Market Cap | 442.05M +119.5% |
| Revenue (ttm) | n/a |
| Net Income | -25.57M |
| EPS | -0.36 |
| Shares Out | 79.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,825 |
| Average Volume | 102,170 |
| Open | 5.50 |
| Previous Close | 5.40 |
| Day's Range | 5.30 - 5.56 |
| 52-Week Range | 2.57 - 8.49 |
| Beta | 0.86 |
| RSI | 34.92 |
| Earnings Date | Apr 2, 2026 |
About NervGen Pharma
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement wi... [Read more]
Financial Performance
Financial StatementsNews
NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium
Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independenc...
NervGen Pharma appoints new president & CEO
NervGen Pharma Appoints Adam Rogers As CEO
(RTTNews) - NervGen Pharma Corp. (NGEN), Monday announced the appointment of Adam Rogers as President and Chief Executive Officer of the company, effective immediately.
NGEN: NervGen Pharma Appoints New CEO to Advance NVG-291
NGEN: NervGen Pharma Appoints New CEO to Advance NVG-291
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury
VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing fi...
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury
NervGen Pharma Debuts On Nasdaq
(RTTNews) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopharmaceutical company developing neuroreparative therapeutics for spinal cord injury and other neurotraumatic and ne...
NervGen Pharma Begins Trading on Nasdaq Today
VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing firs...
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...
NervGen Pharma Announces Proposed Amendment to Warrants
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...
NervGen Pharma GAAP EPS of -$0.06
NervGen Pharma press release (NGENF): Q3 GAAP EPS of -$0.06. NervGen had cash and investments of $11.4 million as of September 30, 2025
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injury Completed a U.S. Foo...
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placebo Par...
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...
NervGen Pharma announces $10M non-brokered private placement
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders
Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal con...
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury
Demonstrated significant hearing restoration in blast-induced sensorineural hearing loss models Promoted significant functional recovery and axonal regeneration in peripheral nerve injury models Reinf...
NervGen Pharma announces CEO transition
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion
Chairman Dr. Adam Rogers Appointed Interim CEO Following Landmark Positive Chronic Spinal Cord Injury Trial Results Vancouver, British Columbia--(Newsfile Corp. - July 17, 2025) - NervGen Pharma Corp....
NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing i...
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth
Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic cohort results of Phase 1b/2a CONNECT SCI Study Vancouver, British Columbia--(Newsfile Corp...
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones
Vancouver, British Columbia--(Newsfile Corp. - July 1, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, ...
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics,...